Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;45(6):365-372.
doi: 10.1159/000497472. Epub 2019 Mar 21.

Amnioinfusions to Treat Early Onset Anhydramnios Caused by Renal Anomalies: Background and Rationale for the Renal Anhydramnios Fetal Therapy Trial

Elizabeth M O'Hare  1 , Angie C Jelin  2 , Jena L Miller  2 , Rodrigo Ruano  3 , Meredith A Atkinson  4 , Ahmet A Baschat  2 , Eric B Jelin  5   6
Affiliations

Amnioinfusions to Treat Early Onset Anhydramnios Caused by Renal Anomalies: Background and Rationale for the Renal Anhydramnios Fetal Therapy Trial

Elizabeth M O'Hare et al. Fetal Diagn Ther. 2019.

Abstract

Anhydramnios caused by early anuria is thought to be universally fatal due to pulmonary hypoplasia. Bilateral renal agenesis and early fetal renal failure leading to anhydramnios constitute early pregnancy renal anhydramnios (EPRA). There have been successful reports of amnioinfusions to promote lung growth in the setting of EPRA. Some of these successfully treated EPRA fetuses have survived the neonatal period, undergone successful dialysis, and subsequently received a kidney transplant. Conversely, there are no reports of untreated EPRA survivors. This early success of amnioinfusions to treat EPRA justifies a rigorous prospective trial. The objective of this study is to provide a review of what is known about fetal therapy for EPRA and describe the Renal Anhydramnios Fetal Therapy trial. We review the epidemiology, pathophysiology, and genetics of EPRA. Furthermore, we have performed systematic review of case reports of treated EPRA. We describe the ethical framework, logistical challenges, and rationale for the current single center (NCT03101891) and planned multicenter trial.

Keywords: Amnioinfusions; Anhydramnios; Bilateral renal agenesis; Pulmonary hypoplasia; Renal replacement therapy.

PubMed Disclaimer

Conflict of interest statement

Statement of Ethics

The authors have no ethical conflicts to disclose. The Johns Hopkins Institutional review Board has approved the single site “Renal Agenesis Fetal Therapy” trial and is actively reviewing the multicenter “RAFT” trial.

Disclosure Statement

The authors declare that they have no conflicts of interest to disclose.

References

    1. Balasundaram M, Chock VY, Wu HY, Blumenfeld YJ, Hintz SR. Predictors of poor neonatal outcomes in prenatally diagnosed multicystic dysplastic kidney disease. J Perinatol. 2018. June;38(6):658–64. - PubMed
    1. Ruano R, Safdar A, Au J, Koh CJ, Gargollo P, Shamshirsaz AA, et al. Defining and predicting ‘intrauterine fetal renal failure’ in congenital lower urinary tract obstruction. Pediatr Nephrol. 2016. April;31(4):605–12. - PubMed
    1. Kizilcan F, Tanyel FC, Cakar N, Büyükpamukçu N, Hiçsönmez A. The effect of low amniotic pressure without oligohydramnios on fetal lung development in a rabbit model. Am J Obstet Gynecol. 1995. July;173(1):36–41. - PubMed
    1. Polzin WJ, Lim FY, Habli M, Van Hook J, Minges M, Jaekle R, et al. Use of an amnioport to maintain amniotic fluid volume in fetuses with oligohydramnios secondary to lower urinary tract obstruction or fetal renal anomalies. Fetal Diagn Ther. 2017;41(1):51–7. - PubMed
    1. Dias T, Sairam S, Kumarasiri S. Ultrasound diagnosis of fetal renal abnormalities. Best Pract Res Clin Obstet Gynaecol. 2014. April; 28(3):403–15. - PubMed

Publication types

Associated data